clinical trial · NCT07144020
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Zhejiang University·early phase1·recruiting·n = 50
Acute Myeloid LeukemiaCD117 CAR T-cells
brief summary
A Clinical Study on the Safety and Effectiveness of Donor Derived CD117 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
started
Sep 5, 2025
primary completion
Sep 5, 2028
completion
Sep 5, 2028
last updated
Aug 27, 2025
detailed description
This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety and efficacy of CD117 CAR-T Cell in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 15-50 participants in this trial.
official title
Donor Derived CD117 CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol